Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoo, Wan-Hee | - |
dc.contributor.author | Kang, Young Mo | - |
dc.contributor.author | Kim, Dong Wook | - |
dc.contributor.author | Kang, Eun Ha | - |
dc.contributor.author | Lee, Yeon-Ah | - |
dc.contributor.author | Suh, Chang-Hee | - |
dc.contributor.author | Sung, Yoon Kyoung | - |
dc.contributor.author | Lee, Sang-Hoon | - |
dc.contributor.author | Gu, Dong-Ha | - |
dc.contributor.author | Lee, Jiwon | - |
dc.contributor.author | Choe, Jung-Yoon | - |
dc.date.accessioned | 2023-05-03T10:20:10Z | - |
dc.date.available | 2023-05-03T10:20:10Z | - |
dc.date.created | 2023-01-05 | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 2198-6576 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/185112 | - |
dc.description.abstract | Introduction SB4 is the first approved biosimilar of etanercept, a biologic tumor necrosis factor inhibitor, to treat various autoimmune diseases including axial spondylarthritis (axSpA), rheumatoid arthritis (RA), psoriatic arthritis (PsA), and plaque psoriasis (PsO). This post-marketing surveillance (PMS) study of SB4 investigated safety and effectiveness in routine clinical practice and is part of the drug approval process in Korea. Methods This prospective, multi-center, open-label, observational, phase IV PMS study was designed to enroll patients with axSpA, RA, PsA, and PsO in Korea from September 2015 to September 2019. Both etanercept-naïve patients or patients switched from reference etanercept were included. SB4 was administered weekly via subcutaneous injections using pre-filled syringes. Safety was assessed by the incidence of adverse events (AEs), adverse drug reactions (ADRs) and serious adverse events (SAE). Effectiveness was assessed by the change from baseline of investigator-rated Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with ankylosing spondylitis (AS) and disease activity score-28 (DAS28) in patients with RA. Results Among 316 enrolled patients, 314 were included in the safety analysis (176 with AS and 138 with RA). The overall incidence of AEs, ADRs and serious AEs were 17.8, 9.9, and 1.3%, respectively. Most AEs were mild (66.7%) or moderate (31.1%) and not related to SB4 (58.9%). Most common AEs were injection site pruritus (1.9%) and injection site rash (1.3%). At week 24, mean disease activity scores significantly decreased compared to baseline in naïve patients with AS and RA (BASDAI 2.7 vs. 6.2, p < 0.0001; DAS28 3.8 vs. 5.7, p < 0.0001) and in switched patients with AS and RA (BASDAI 1.0 vs. 1.3, p = 0.0018; DAS28 2.4 vs. 2.9, p = 0.0893). Conclusion This first real-world evidence of SB4 from a phase IV PMS study in Korea shows comparable effectiveness to historical SB4 real-world evidence without any new significant safety signals. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.title | Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Sung, Yoon Kyoung | - |
dc.identifier.doi | 10.1007/s40744-022-00515-z | - |
dc.identifier.scopusid | 2-s2.0-85143653439 | - |
dc.identifier.wosid | 000895605500001 | - |
dc.identifier.bibliographicCitation | RHEUMATOLOGY AND THERAPY, v.10, no.2, pp.329 - 341 | - |
dc.relation.isPartOf | RHEUMATOLOGY AND THERAPY | - |
dc.citation.title | RHEUMATOLOGY AND THERAPY | - |
dc.citation.volume | 10 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 329 | - |
dc.citation.endPage | 341 | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Early Access | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Rheumatology | - |
dc.relation.journalWebOfScienceCategory | Rheumatology | - |
dc.subject.keywordPlus | ARTHRITIS | - |
dc.subject.keywordPlus | PATIENT | - |
dc.subject.keywordAuthor | SB4 | - |
dc.subject.keywordAuthor | Etanercept | - |
dc.subject.keywordAuthor | Biosimilar | - |
dc.subject.keywordAuthor | Post-marketing surveillance | - |
dc.subject.keywordAuthor | Real-world evidence | - |
dc.subject.keywordAuthor | Safety | - |
dc.subject.keywordAuthor | Effectiveness | - |
dc.subject.keywordAuthor | Ankylosing spondylitis | - |
dc.subject.keywordAuthor | Rheumatoid arthritis | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s40744-022-00515-z | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.